Osprey Medical Inc. PRESERV Clinical Trial Update
June 07 2013 - 4:05PM
Business Wire
- In March 2013, Osprey Medical announced
commencement of its US registration directed pivotal IDE clinical
study of the CINCOR™ system with the first patient enrolled at the
Leipzig Heart Centre in Germany.
- In May 2013, Dr Richard Heuser enrolled
the first two US patients at St. Luke’s Medical Center in Phoenix,
Arizona.
- As of May 31, 2013, twelve hospitals
have Institutional Review Board (IRB) and contract approval
and are actively screening patients for trial enrollment.
- The CINCOR dye reduction and removal
system limits the amount of dye used in a heart procedure from
reaching the kidneys, thereby reducing the risk of Contrast Induced
Nephropathy (CIN), a form of acute kidney injury, in
patients undergoing common heart procedures.
Osprey Medical (ASX:OSP)
Historical Stock Chart
From Apr 2024 to May 2024
Osprey Medical (ASX:OSP)
Historical Stock Chart
From May 2023 to May 2024